ResearcherNational Cancer Center Exploratory Oncology Research & Clinical Trial CenterNo recent work listed

Rumi Fujioka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5004404130. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper

Papers 2

Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1371/journal.pone.0198219 ↗
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. Co-author DOI 10.1111/cas.13086 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hiroyasu Esumi · 2 shared papers, 2016–2018 · strength 0.13
- Paper Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with ge… DOI 10.1371/journal.pone.0198219 ↗
- Paper Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. DOI 10.1111/cas.13086 ↗
Masafumi Ikeda · 2 shared papers, 2016–2018 · strength 0.13
- Paper Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with ge… DOI 10.1371/journal.pone.0198219 ↗
- Paper Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. DOI 10.1111/cas.13086 ↗
Satoshi Owada · 1 shared paper, 2018 · strength 0.08
- Paper Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with ge… DOI 10.1371/journal.pone.0198219 ↗
Shuichi Mitsunaga · 1 shared paper, 2016 · strength 0.05
- Paper Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. DOI 10.1111/cas.13086 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.